KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Divestments (2020 - 2025)

Royalty Pharma's Divestments history spans 3 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Divestments rose 53.95% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $56.0 million, up 136.83%, while the annual FY2025 figure was $105.1 million, 344.77% up from the prior year.
  • Divestments for Q4 2025 was $5.0 million at Royalty Pharma, down from $36.3 million in the prior quarter.
  • Across five years, Divestments topped out at $36.3 million in Q1 2025 and bottomed at $3.2 million in Q4 2024.
  • The 3-year median for Divestments is $5.0 million (2025), against an average of $14.2 million.
  • The largest annual shift saw Divestments crashed 85.72% in 2024 before it soared 630.35% in 2025.
  • A 3-year view of Divestments shows it stood at $34.8 million in 2023, then crashed by 90.67% to $3.2 million in 2024, then soared by 53.95% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Divestments are $5.0 million (Q4 2025), $36.3 million (Q1 2025), and $3.2 million (Q4 2024).